oxybutynin and Back Pain studies

oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.

Back Pain: Acute or chronic pain located in the posterior regions of the THORAX; LUMBOSACRAL REGION; or the adjacent regions.

Research Excerpts

Excerpt	Relevance	Reference
"The 5% Lidocaine patch is used for treating chronic neuropathic pain conditions such as chronic back pain (CBP), diabetic neuropathy and complex regional pain syndrome, but is effective in a variable proportion of patients."	9.16	Lidocaine patch (5%) is no more potent than placebo in treating chronic back pain when tested in a randomised double blind placebo controlled brain imaging study. ( Apkarian, AV; Baliki, MN; Chanda, ML; Hashmi, JA; Huang, L; Parks, EL; Schnitzer, T, 2012)
" Fifteen patients experienced a total of 19 adverse events (AEs), 17 of which were mild to moderate, and 2 of which were severe."	6.76	Effectiveness and safety of diclofenac epolamine topical patch 1.3% for the treatment of acute pain due to back strain: an open-label, uncontrolled study. ( Gimbel, J; Jacobs, D; Paterson, C; Pixton, G, 2011)
"The 5% Lidocaine patch is used for treating chronic neuropathic pain conditions such as chronic back pain (CBP), diabetic neuropathy and complex regional pain syndrome, but is effective in a variable proportion of patients."	5.16	Lidocaine patch (5%) is no more potent than placebo in treating chronic back pain when tested in a randomised double blind placebo controlled brain imaging study. ( Apkarian, AV; Baliki, MN; Chanda, ML; Hashmi, JA; Huang, L; Parks, EL; Schnitzer, T, 2012)
" Fifteen patients experienced a total of 19 adverse events (AEs), 17 of which were mild to moderate, and 2 of which were severe."	2.76	Effectiveness and safety of diclofenac epolamine topical patch 1.3% for the treatment of acute pain due to back strain: an open-label, uncontrolled study. ( Gimbel, J; Jacobs, D; Paterson, C; Pixton, G, 2011)

Research

Studies (6)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

Brief Pain Inventory-Short Form (BPI-SF)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	6 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Castro, E	1
Dent, D	1
da Cruz, CM	1
Antunes, F	1
Trist, AJ	1
Sahota, H	1
Williams, L	1
Gimbel, J	1
Jacobs, D	1
Pixton, G	1
Paterson, C	1
Hashmi, JA	1
Baliki, MN	1
Huang, L	1
Parks, EL	1
Chanda, ML	1
Schnitzer, T	1
Apkarian, AV	1

Trial	Enrollment	Study Type	Start Date	Status
Mind-body Treatments for Chronic Back Pain[NCT03294148]	151 participants (Actual)	Interventional	2017-08-07	Completed
Randomized, Placebo-controlled Crossover Trial Evaluating Topical Lidocaine Patch(es) for Mechanical Neck Pain.[NCT04378959]	76 participants (Actual)	Interventional	2021-02-01	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

1-week average pain intensity, 0 - 10 numerical rating scale, where a higher score indicates more pain. (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization

Negative Affect Scale Short Form (PANAS-SF)

Intervention	units on a scale (Mean)
Pain Reprocessing Therapy (PRT)	1.18
Placebo	2.84
Usual Care	3.13

Questionnaire to rate negative affect, scores range from 5 - 25, with a higher score meaning a stronger negative affect (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization

Oswestry Disability Index

Intervention	score on a scale (Mean)
Pain Reprocessing Therapy (PRT)	8.30
Placebo	7.70
Usual Care	8.19

Back pain disability questionnaire measured on a scale of 0-100. A higher score indicates a higher severity of disability. (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization

Pain Catastrophizing Questionnaire (PCS)

Intervention	score on a scale (Mean)
Pain Reprocessing Therapy (PRT)	10.14
Placebo	19.00
Usual Care	20.68

Questionnaire used to help quantify an individual's pain experience. Measured 0-52. A higher score means a higher level of catastrophizing. (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization

Patient Global Impression of Change (PGIC)

Intervention	score on a scale (Mean)
Pain Reprocessing Therapy (PRT)	8.30
Placebo	7.70
Usual Care	8.19

Post-treatment-only outcome measure depicting a patient's subjective rating of overall improvement. Score ranges from 1-7 with a higher score indicating a higher level of change and improvement (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization

Positive Affect Scale Short Form (PANAS-SF)

Intervention	score on a scale (Mean)
Pain Reprocessing Therapy (PRT)	6.14
Placebo	3.61
Usual Care	2.06

Questionnaire to rate positive affect, scores range from 5 - 25, a higher score means stronger affect (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization

PROMIS Anger

Intervention	score on a scale (Mean)
Pain Reprocessing Therapy (PRT)	17.89
Placebo	15.20
Usual Care	14.98

Questionnaire measuring anger (5 items) with a score range of 5-25. Higher scores indicate a higher severity of anger. (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization

PROMIS Anxiety

Intervention	score on a scale (Mean)
Pain Reprocessing Therapy (PRT)	9.52
Placebo	9.89
Usual Care	10.45

Questionnaire measuring anxiety (8 items). Scores range from 8-40 with a higher score meaning more severe levels of fear, anxious misery, hyperarousal, and somatic symptoms related to arousal. (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization

PROMIS Sleep

Intervention	score on a scale (Mean)
Pain Reprocessing Therapy (PRT)	15.02
Placebo	13.89
Usual Care	14.11

Questionnaire measuring sleep disturbance (8 items). Scores range from 8-40. Higher scores indicate higher levels of sleep disturbance (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization

PROMIS- Depression

Intervention	score on a scale (Mean)
Pain Reprocessing Therapy (PRT)	17.73
Placebo	20.50
Usual Care	20.89

Questionnaire measuring depression (8 items). Scores range from 8-32. A higher score indicates higher levels of depressive symptoms (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization

Tampa Scale of Kinesiophobia (TSK)

Intervention	score on a scale (Mean)
Pain Reprocessing Therapy (PRT)	12.23
Placebo	11.75
Usual Care	11.81

Questionnaire used to assess the subjective rating of kinesiophobia or fear of movement. Scores range from 11-44 with higher scores indicating greater fear of pain, movement, and injury. (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization

Timeline Follow-Back Measure for Alcohol (TLFB)

Intervention	score on a scale (Mean)
Pain Reprocessing Therapy (PRT)	16.41
Placebo	22.16
Usual Care	22.51

Questionnaire used to assess daily drinking (number of drinks consumed over past two weeks) (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization

Timeline Follow-Back Measure for Cannabis (TLFB)

Intervention	Drinks (Mean)
Pain Reprocessing Therapy (PRT)	11.63
Placebo	12.88
Usual Care	8.02

Questionnaire used to assess daily cannabis use (number of grams consumed over past two weeks) (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization

Timeline Follow-Back Measure for Opioid Use (TLFB)

Intervention	Grams of cannabis (Mean)
Pain Reprocessing Therapy (PRT)	6.76
Placebo	3.31
Usual Care	1.49

Questionnaire used to assess daily opioid use (number of pills consumed over past two weeks) (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization

Treatment Satisfaction Questionnaire

Intervention	Opioid pills (Mean)
Pain Reprocessing Therapy (PRT)	1.29
Placebo	0.36
Usual Care	1.77

Post-treatment-only outcome measure depicting the patient's satisfaction with the treatment. Measured 0 - 100. A higher score means higher satisfaction with treatment/ (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization

Article	Year
A comparison of transdermal over-the-counter lidocaine 3.6% menthol 1.25%, Rx lidocaine 5% and placebo for back pain and arthritis. Pain management, 2017, Volume: 7, Issue:6 Topics: Administration, Cutaneous; Anesthetics, Local; Arthritis; Back Pain; Double-Blind Method; Drug Combi	2017
Effectiveness and safety of diclofenac epolamine topical patch 1.3% for the treatment of acute pain due to back strain: an open-label, uncontrolled study. The Physician and sportsmedicine, 2011, Volume: 39, Issue:1 Topics: Acute Pain; Administration, Topical; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroida	2011
Lidocaine patch (5%) is no more potent than placebo in treating chronic back pain when tested in a randomised double blind placebo controlled brain imaging study. Molecular pain, 2012, Apr-24, Volume: 8 Topics: Back Pain; Brain; Brain Mapping; Chronic Pain; Double-Blind Method; Female; Humans; Lidocaine; Magne	2012
Lidocaine patch (5%) is no more potent than placebo in treating chronic back pain when tested in a randomised double blind placebo controlled brain imaging study. Molecular pain, 2012, Apr-24, Volume: 8 Topics: Back Pain; Brain; Brain Mapping; Chronic Pain; Double-Blind Method; Female; Humans; Lidocaine; Magne	2012
Lidocaine patch (5%) is no more potent than placebo in treating chronic back pain when tested in a randomised double blind placebo controlled brain imaging study. Molecular pain, 2012, Apr-24, Volume: 8 Topics: Back Pain; Brain; Brain Mapping; Chronic Pain; Double-Blind Method; Female; Humans; Lidocaine; Magne	2012
Lidocaine patch (5%) is no more potent than placebo in treating chronic back pain when tested in a randomised double blind placebo controlled brain imaging study. Molecular pain, 2012, Apr-24, Volume: 8 Topics: Back Pain; Brain; Brain Mapping; Chronic Pain; Double-Blind Method; Female; Humans; Lidocaine; Magne	2012

Article	Year
Not so patchy story of attempted suicide…leading to 24 hours of deep sleep and survival! BMJ case reports, 2017, Jan-17, Volume: 2017 Topics: Aged; Analgesics, Opioid; Back Pain; Chronic Pain; Drug Overdose; Female; Fentanyl; Humans; Suicide,	2017
I just started using a fentanyl patch for chronic back pain. What special precautions should I take? The Johns Hopkins medical letter health after 50, 2012, Volume: 24, Issue:8 Topics: Administration, Cutaneous; Analgesics, Opioid; Back Pain; Chronic Disease; Fentanyl; Humans; Patient	2012

oxybutynin and Back Pain